Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Review Article

Discharge Planning for People with Inpatient Hyperglycaemia: A Review on Pharmacological Management

Author(s): Kalyan Kumar Gangopadhyay*, Rakesh Kumar Sahay, Sunil Gupta, Vageesh Ayyar, Sambit Das, Saptarshi Bhattacharya, Sudhir Bhandari and Arpandev Bhattacharyya

Volume 19, Issue 9, 2023

Published on: 31 March, 2023

Article ID: e240223214030 Pages: 17

DOI: 10.2174/1573399819666230224123707

Price: $65

Abstract

Inadequate glycaemic control post-discharge is the root cause of readmission in people with diabetes mellitus (DM) and is often linked to improper discharge planning (DP). A structured DP plays a crucial role in ensuring continuing home care and avoiding readmissions. DP should help patients in self-care and provide appropriate guidance to maintain optimal glycaemic control. There is a scarcity of reports and recommendations on the proper DP for people with DM on insulin therapy. The present review provides important consideration based on experts’ opinions from the National Insulin and Incretin summit (NIIS), focusing on the effective treatment strategies at the time of discharge, especially for insulin therapy. A review of literature from PubMed and Embase was conducted. The consensus was derived, and recommendations were made on effective DP for patients with DM. Recommendations were drawn at the NIIS for post-discharge treatment for medical and surgical cases, stress-induced hyperglycaemia, elderly, pregnant women, and coronavirus disease 2019 (COVID-19) cases. The committee also recommended a comprehensive checklist to assist the physicians during discharge.

[1]
Home - IDF Virtual Congress 2021. IDF 2021. Available From: https://idf2021.org/
[2]
Pandey A, Ploubidis GB, Clarke L, Dandona L. Hospitalisation trends in India from serial cross-sectional nationwide surveys: 1995 to 2014. BMJ Open 2017; 7(12): e014188.
[http://dx.doi.org/10.1136/bmjopen-2016-014188]
[3]
Gangopadhyay KK, Bantwal G, Talwalkar PG, Muruganathan A, Das AK. Consensus evidence-based guidelines for in-patient management of hyperglycaemia in non-critical care setting as per Indian clinical practice. J Assoc Physicians India 2014; 62(7) (Suppl.): 6-15.
[PMID: 25668932]
[4]
Pugh J, Penney LS, Noël PH, Neller S, Mader M, Finley EP, et al. Evidence based processes to prevent readmissions: More is better, a ten-site observational study. BMC Health Serv Res 2021; 21(1): 189.
[http://dx.doi.org/10.1186/s12913-021-06193-x]
[5]
Shepperd S, Lannin NA, Clemson LM, McCluskey A, Cameron ID, Barras SL. Discharge planning from hospital to home. Cochrane Database Syst Rev 2013; (1): CD000313.
[http://dx.doi.org/10.1002/14651858.CD000313.pub4]
[6]
Zurlo A, Zuliani G. Management of care transition and hospital discharge. Aging Clin Exp Res 2018; 30(3): 263-70.
[http://dx.doi.org/10.1007/s40520-017-0885-6] [PMID: 29313293]
[7]
Lin CJ, Cheng SJ, Shih SC, Chu CH, Tjung JJ. Discharge planning. Int J Gerontol 6(4): 237-40.
[http://dx.doi.org/10.1016/j.ijge.2012.05.001]
[8]
Bain A, Nettleship L, Kavanagh S, Babar ZUD. Evaluating insulin information provided on discharge summaries in a secondary care hospital in the United Kingdom. J Pharm Policy Pract 2017; 10(1): 25. Available From: https://link.gale.com/apps/doc/A501523838/HRCA?u=anon~a0307c91&sid=googleScholar&xid=6c83e35e
[http://dx.doi.org/10.1186/s40545-017-0113-y] [PMID: 28852529]
[9]
Umpierrez GE, Reyes D, Smiley D, et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care 2014; 37(11): 2934-9.
[http://dx.doi.org/10.2337/dc14-0479] [PMID: 25168125]
[10]
Donihi AC. Practical recommendations for transitioning patients with type 2 diabetes from hospital to home. Curr Diab Rep 2017; 17(7): 52.
[http://dx.doi.org/10.1007/s11892-017-0876-1] [PMID: 28573408]
[11]
Cadel L, Guilcher SJT, Kokorelias KM, et al. Initiatives for improving delayed discharge from a hospital setting: a scoping review. BMJ Open 2021; 11(2): e044291.
[http://dx.doi.org/10.1136/bmjopen-2020-044291] [PMID: 33574153]
[12]
Henke RM, Karaca Z, Jackson P, Marder WD, Wong HS. Discharge planning and hospital readmissions. Med Care Res Rev 2017; 74(3): 345-68.
[http://dx.doi.org/10.1177/1077558716647652] [PMID: 27147642]
[13]
Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: A systematic review. Arch Intern Med 2012; 172(14): 1057-69.
[http://dx.doi.org/10.1001/archinternmed.2012.2246] [PMID: 22733210]
[14]
Hoyer EH, Odonkor CA, Bhatia SN, Leung C, Deutschendorf A, Brotman DJ. Association between days to complete inpatient discharge summaries with all-payer hospital readmissions in Maryland. J Hosp Med 2016; 11(6): 393-400.
[http://dx.doi.org/10.1002/jhm.2556] [PMID: 26913814]
[15]
Nassar CM, Montero A, Magee MF. Inpatient diabetes education in the real world: An overview of guidelines and delivery models. Curr Diab Rep 2019; 19(10): 103.
[http://dx.doi.org/10.1007/s11892-019-1222-6] [PMID: 31515653]
[16]
Alper E. Hospital discharge and readmission - UpToDate Uptodatecom 2022. Available from: https://www.uptodate.com/contents/hospital-discharge-and-readmission
[17]
Patel PR, Bechmann S. Discharge Planning. Treasure Island, FL: StatPearls Publishing 2022. Internet Available from: https://www.ncbi.nlm.nih.gov/books/NBK557819/
[18]
Coffey A, Leahy-Warren P, Savage E, Hegarty J, Cornally N, Day MR, et al. Interventions to promote early discharge and avoid inappropriate hospital (Re)admission: A systematic review. Int J Environ Res Public Health 2019; 16(14): 2457.
[http://dx.doi.org/10.3390/ijerph16142457]
[19]
Magny-Normilus C, Nolido NV, Borges JC, et al. Effects of an intensive discharge intervention on medication adherence, glycemic control, and readmission rates in patients with type 2 diabetes. J Patient Saf 2021; 17(2): 73-80.
[http://dx.doi.org/10.1097/PTS.0000000000000601] [PMID: 31009408]
[20]
Becker C, Zumbrunn S, Beck K, et al. Interventions to improve communication at hospital discharge and rates of readmission. JAMA Netw Open 2021; 4(8): e2119346.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.19346] [PMID: 34448868]
[21]
Dehnabi A, Radsepehr H, Navipour H. Evaluating the effect of discharge planning on glycosylated hemoglobin level in type 2 diabetic patients who referred to the vasei hospital in sabzevar, iran: an interventional study Med Surg Nurs J 7(3): e87197.
[http://dx.doi.org/10.5812/msnj.87197]
[22]
Dhatariya K, Corsino L, Umpierrez GE. Management of Diabetes and Hyperglycemia in Hospitalized PatientsEndotext South Dartmouth (MA): MDTextcom, Inc. Feingold KR 2020.
[23]
Tamez-Pérez HE, Quintanilla-Flores DL, Proskauer-Peña SL, et al. Inpatient hyperglycemia: Clinical management needs in teaching hospital. J Clin Transl Endocrinol 2014; 1(4): 176-8.
[http://dx.doi.org/10.1016/j.jcte.2014.09.004] [PMID: 29159098]
[24]
Wei NJ, Nathan DM, Wexler DJ. Glycemic control after hospital discharge in insulin-treated type 2 diabetes: A randomized pilot study of daily remote glucose monitoring. Endocr Pract 2015; 21(2): 115-21.
[http://dx.doi.org/10.4158/EP14134.OR] [PMID: 25148814]
[25]
Fuller TE, Pong DD, Piniella N, et al. Interactive digital health tools to engage patients and caregivers in discharge preparation: Implementation study. J Med Internet Res 2020; 22(4): e15573.
[http://dx.doi.org/10.2196/15573] [PMID: 32343248]
[26]
Pollack TA, Illuri V, Khorzad R, et al. Risk assessment of the hospital discharge process of high-risk patients with diabetes. BMJ Open Qual 2018; 7(2): e000224.
[http://dx.doi.org/10.1136/bmjoq-2017-000224] [PMID: 29862328]
[27]
Wexler DJ, Beauharnais CC, Regan S, Nathan DM, Cagliero E, Larkin ME. Impact of inpatient diabetes management, education, and improved discharge transition on glycemic control 12 months after discharge. Diabetes Res Clin Pract 2012; 98(2): 249-56.
[http://dx.doi.org/10.1016/j.diabres.2012.09.016] [PMID: 23036785]
[28]
Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol 2021; 9(3): 174-88.
[http://dx.doi.org/10.1016/S2213-8587(20)30381-8] [PMID: 33515493]
[29]
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020; 43 (Suppl. 1): S66-76.
[http://dx.doi.org/10.2337/dc20-S006] [PMID: 31862749]
[30]
Peterson G. Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia. Hosp Pract 2011; 39(4): 87-95.
[http://dx.doi.org/10.3810/hp.2011.10.927] [PMID: 22056828]
[31]
Carol J. Discharge planning for adult with diabetes (JBDS-IP) Diabetesorguk 2022. Available from: JBDS_2022 _10_Discharge_Planning_Guideline_240122.pdf
[32]
Kang E, Gillespie BM, Tobiano G, Chaboyer W. Discharge education delivered to general surgical patients in their management of recovery post discharge: A systematic mixed studies review. Int J Nurs Stud 2018; 87: 1-13.
[http://dx.doi.org/10.1016/j.ijnurstu.2018.07.004] [PMID: 30015088]
[33]
Kuan IHS, Wilson LC, Leishman JC, et al. Metformin doses to ensure efficacy and safety in patients with reduced kidney function. PLoS One 2021; 16(2): e0246247.
[http://dx.doi.org/10.1371/journal.pone.0246247] [PMID: 33600406]
[34]
Lebovitz HE. Thiazolidinediones: The forgotten diabetes medications. Curr Diab Rep 2019; 19(12): 151.
[http://dx.doi.org/10.1007/s11892-019-1270-y] [PMID: 31776781]
[35]
D’Souza SC, Kruger DF. Considerations for insulin-treated type 2 diabetes patients during hospitalization: A narrative review of what we need to know in the age of second-generation basal insulin analogs. Diabetes Ther 2020; 11(12): 2775-90.
[http://dx.doi.org/10.1007/s13300-020-00920-z] [PMID: 33000382]
[36]
Ruan Y, Tan GD, Lumb A, Rea RD. Importance of inpatient hypoglycaemia: Impact, prediction and prevention. Diabet Med 2019; 36(4): 434-43.
[http://dx.doi.org/10.1111/dme.13897] [PMID: 30653706]
[37]
Sonmez H, Kambo V, Taha R, Poretsky L. Reducing hospital re-admissions in patients with diabetes: Developing better strategies. Endocr Pract 2016; 22(9): 1134-6.
[http://dx.doi.org/10.4158/EP161315.CO] [PMID: 27359289]
[38]
Shacham EC, Nitzan R, Schwartz N, Ishay A. Effects of recommendations for diabetes management at hospital discharge on long-term diabetes control. Endocr Pract 2021; 27(2): 118-23.
[http://dx.doi.org/10.1016/j.eprac.2020.09.009] [PMID: 33616045]
[39]
Abusamaan MS, Fesseha Voss B, Kim HN, Reyes-DeJesus D, Langan S, Niessen TM, et al. Patterns and predictors of antihyperglycemic intensification at hospital discharge for type 2 diabetic patients not on home insulin. J Clin Transl Endocrinol 2020; 20: 100220.
[http://dx.doi.org/10.1016/j.jcte.2020.100220]
[40]
Lavernia F. Treating hyperglycemia and diabetes with insulin therapy: Transition from inpatient to outpatient care. Medscape J Med 2008; 10(9): 216.
[PMID: 19008977]
[41]
Simioni N, Filippi A, Scardapane M, Nicolucci A, Rossi MC, Frison V. Efficacy and safety of insulin degludec for hyperglycemia management in noncritical hospitalized patients with diabetes: An observational study. Diabetes Ther 2017; 8(4): 941-6.
[http://dx.doi.org/10.1007/s13300-017-0271-6] [PMID: 28585180]
[42]
Joshi SR, Wangnoo SK, Chowdhury S, et al. Indian reality of clinical practice and patient profile in diabetes care: Lessons from the IMPACT survey. J Assoc Physicians India 2022; 70(5): 11-2.
[PMID: 35598134]
[43]
Philis-Tsimikas A, Astamirova K, Gupta Y, et al. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract 2019; 147: 157-65.
[http://dx.doi.org/10.1016/j.diabres.2018.10.024] [PMID: 30448451]
[45]
Mehta R, Chen R, Hirose T, et al. Practical use of insulin degludec/insulin aspart in a multinational setting: Beyond the guidelines. Diabetes Obes Metab 2020; 22(11): 1961-75.
[http://dx.doi.org/10.1111/dom.14128] [PMID: 32618405]
[46]
Davis A, Kuriakose J, Clements JN. Faster insulin aspart: A new bolus option for diabetes mellitus. Clin Pharmacokinet 2019; 58(4): 421-30.
[http://dx.doi.org/10.1007/s40262-018-0696-8] [PMID: 29978361]
[47]
Kesavadev J, Saboo B, Krishna MB, Krishnan G. Evolution of insulin delivery devices: From syringes, pens, and pumps to diy artificial pancreas. Diabetes Ther 2020; 11(6): 1251-69.
[http://dx.doi.org/10.1007/s13300-020-00831-z] [PMID: 32410184]
[48]
Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE Jr. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev 2020; 41(5): 733-55.
[http://dx.doi.org/10.1210/endrev/bnaa015] [PMID: 32396624]
[49]
Singh AK. Science of premix insulin: Where have we reached? Expert Rev Endocrinol Metab 2015; 10(1): 65-74.
[http://dx.doi.org/10.1586/17446651.2015.961914] [PMID: 30289040]
[50]
Awang Husaini DNH B, Siong Keasberry JF, Abdul Mumin K H, Abdul Rahman H. Causes of discharge delays from the acute medical unit (AMU) in a tertiary level teaching hospital, Brunei Darussalam. Proceedings of Singapore Healthcare 2021; 1-8.
[http://dx.doi.org/10.1177/20101058211006143]
[51]
Sudhakaran S, Surani SR. Guidelines for perioperative management of the diabetic patient. Surg Res Pract 2015; 2015: 1-8.
[http://dx.doi.org/10.1155/2015/284063] [PMID: 26078998]
[52]
Wang J, Chen J, Li X, Jin X, An P, Fang Y, et al. Postoperative adverse events in patients with diabetes undergoing orthopedic and general surgery. Medicine 2019; 98(14): e15089.
[http://dx.doi.org/10.1097/MD.0000000000015089]
[53]
American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020; 43 (Suppl. 1): S152-62.
[http://dx.doi.org/10.2337/dc20-S012] [PMID: 31862755]
[54]
Panikar V, Sosale A, Agarwal S, et al. RSSDI clinical practice recommendations for management of In-hospital hyperglycaemia—2016. Int J Diabetes Dev Ctries 2016; 36(S1): 1-21.
[http://dx.doi.org/10.1007/s13410-016-0528-z]
[55]
Kuritzky L, Reid TS, Wysham CH. Practical guidance on effective basal insulin titration for primary care providers. Clin Diabetes 2019; 37(4): 368-76.
[http://dx.doi.org/10.2337/cd18-0091] [PMID: 31660010]
[56]
Ziegler R, Freckmann G, Heinemann L. Boluses in insulin therapy. J Diabetes Sci Technol 2017; 11(1): 165-71.
[http://dx.doi.org/10.1177/1932296816653142] [PMID: 27271845]
[57]
Dowey R, Iqbal A, Heller SR, Sabroe I, Prince LR. A bittersweet response to infection in diabetes; targeting neutrophils to modify inflammation and improve host immunity. Front Immunol 2021; 12: 678771.
[http://dx.doi.org/10.3389/fimmu.2021.678771]
[58]
Ruzycki SM, Harrison TG, Enns E, McKeen J, Helmle K, Cameron A. Quality gaps in screening and monitoring for postoperative hyperglycemia in a Canadian hospital: A retrospective cohort study. BMJ Open Diabetes Res Care 2021; 9(1): e002445.
[http://dx.doi.org/10.1136/bmjdrc-2021-002445] [PMID: 34711544]
[59]
Sarfo-Adu BN, Hendley JL, Pick B, Oyibo SO. Glycemic control during enteral tube feeding in patients with diabetes mellitus. Cureus 2019; 11(1): e3929.
[http://dx.doi.org/10.7759/cureus.3929]
[60]
Campos-Martín C, García-Torres MD, Castillo-Martín C, Domínguez-Rabadán R, Rabat-Restrepo JM. Patients discharged with home enteral nutrition from a third-level hospital in 2018. Nutrients 2019; 11(11): 2570.
[http://dx.doi.org/10.3390/nu11112570] [PMID: 31653019]
[61]
Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab 2017; 19(7): 1032-9.
[http://dx.doi.org/10.1111/dom.12938] [PMID: 28295934]
[62]
Lecumberri E, Ortega M, Iturregui M, Quesada JA, Vázquez C, Orozco D. Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec. Curr Med Res Opin 2018; 34(6): 1053-9.
[http://dx.doi.org/10.1080/03007995.2017.1419172] [PMID: 29300101]
[63]
Galasso S, Facchinetti A, Bonora BM, et al. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. Nutr Metab Cardiovasc Dis 2016; 26(12): 1112-9.
[http://dx.doi.org/10.1016/j.numecd.2016.08.002] [PMID: 27618501]
[64]
Chudasama RK, Kadri AM, Ratnu A, Jain M, Kamariya CP. Magnitude of gestational diabetes mellitus, its influencing factors and diagnostic accuracy of capillary blood testing for its detection at a tertiary care centre, rajkot, Gujarat. Indian J Community Med 2019; 44(2): 142-6.
[PMID: 31333293]
[65]
Kalra P, Anakal M. Peripartum management of diabetes. Indian J Endocrinol Metab 2013; 17(7) (Suppl. 1): 72.
[http://dx.doi.org/10.4103/2230-8210.119510] [PMID: 24251226]
[66]
Pal SA, Ali MI. Management of labour in pregnancy complicated by diabetes. J Pak Med Assoc 2016; 66(9) (Suppl. 1): S85-8.
[PMID: 27640990]
[67]
American Diabetes Association. 13. Management of diabetes in pregnancy. Diabetes Care 2017; 40 (Suppl. 1): S114-9.
[http://dx.doi.org/10.2337/dc17-S016] [PMID: 27979900]
[68]
Matsunaga M, Kataoka Y, Igarashi Y, Fukui T, Imura M, Horiuchi S. Breastfeeding support and barriers to women with gestational diabetes mellitus: A nationwide cross-sectional survey of hospitals in Japan. BMC Pregnancy Childbirth 2021; 21(1): 555.
[http://dx.doi.org/10.1186/s12884-021-04032-9]
[69]
Much D, Beyerlein A, Roßbauer M, Hummel S, Ziegler AG. Beneficial effects of breastfeeding in women with gestational diabetes mellitus. Mol Metab 2014; 3(3): 284-92.
[http://dx.doi.org/10.1016/j.molmet.2014.01.002] [PMID: 24749058]
[70]
Gupta Y, Goyal A, Kubihal S, Golla KK, Tandon N. A guidance on diagnosis and management of hyperglycemia at COVID care facilities in India. Diabetes Metab Syndr 2021; 15(1): 407-13.
[http://dx.doi.org/10.1016/j.dsx.2021.01.015] [PMID: 33581594]
[71]
Coppelli A, Giannarelli R, Aragona M, et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: The pisa COVID-19 study. Diabetes Care 2020; 43(10): 2345-8.
[http://dx.doi.org/10.2337/dc20-1380] [PMID: 32788285]
[72]
Bhattacharyya S. Efficacy and safety of once-daily fixed-ratio coformulation of degludec-aspart plus empa-lina 25/5 fdc in postdischarge COVID-19 pneumonitis T2DM patients treated with dexamethasone during inpatient stay. Diabetes 2021; 70(suppl 1) Available From: https://professional.diabetes.org/meeting/scientific-sessions/81st-scientific-sessions-0 Assessed April 27, 2022.
[73]
Sosale A, Sosale B, Kesavadev J, et al. Steroid use during COVID-19 infection and hyperglycemia – What a physician should know. Diabetes Metab Syndr 2021; 15(4): 102167.
[http://dx.doi.org/10.1016/j.dsx.2021.06.004] [PMID: 34186344]
[74]
Mills ES, Elman MB, Foran JRH. The risk of acute infection following intra-articular corticosteroid injection into a pre-existing total knee arthroplasty. J Arthroplasty 2018; 33(1): 216-9.
[http://dx.doi.org/10.1016/j.arth.2017.07.029] [PMID: 28811109]
[75]
Geier C. Health care improvements in India. The borgen project 2018. Available From: https://borgenproject.org/health-care-improvements-in-india/
[76]
Chentli F, Azzoug S, Mahgoun S. Diabetes mellitus in elderly. Indian J Endocrinol Metab 2015; 19(6): 744-52.
[http://dx.doi.org/10.4103/2230-8210.167553] [PMID: 26693423]
[77]
Eriksson JG, Laine MK. Insulin therapy in the elderly with type 2 diabetes. Minerva Endocrinol 2015; 40(4): 283-95.
[PMID: 26350101]
[78]
Krones R, Schütte C, Heise T. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab 2009; 11(1): 41-4.
[http://dx.doi.org/10.1111/j.1463-1326.2008.00988.x] [PMID: 19120432]
[79]
Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs Aging 2014; 31(1): 47-53.
[http://dx.doi.org/10.1007/s40266-013-0138-0] [PMID: 24263619]
[80]
Fulcher G, Mehta R, Fita EG, Ekelund M, Bain SC. Efficacy and safety of idegasp versus biasp 30, both twice daily, in elderly patients with type 2 diabetes: Post hoc analysis of two phase 3 randomized controlled BOOST trials. Diabetes Ther 2019; 10(1): 107-18.
[http://dx.doi.org/10.1007/s13300-018-0531-0] [PMID: 30474818]
[81]
Wright BM, Bellone JM, Mccoy EK. A review of insulin pen devices and use in the elderly diabetic population Clin Med Insights Endocrinol Diabetes 2010; 3: CMED.S5534.
[http://dx.doi.org/10.4137/CMED.S5534] [PMID: 22879787]
[82]
Gudiksen N, Hofstätter T, Rønn BB, Sparre T. FlexTouch: An insulin pen-injector with a low activation force across different insulin formulations, needle technologies, and temperature conditions. Diabetes Technol Ther 2017; 19(10): 603-7.
[http://dx.doi.org/10.1089/dia.2017.0121] [PMID: 28704062]
[83]
Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. FlexTouch: A prefilled insulin pen with a novel injection mechanism with consistent high accuracy at low- (1 U), medium- (40 U), and high- (80 U) dose settings. J Diabetes Sci Technol 2011; 5(5): 1195-9.
[http://dx.doi.org/10.1177/193229681100500525] [PMID: 22027317]
[84]
Mukherjee JJ, Rajput R, Majumdar S, Saboo B, Chatterjee S. Practical aspects of usage of insulin in India: Descriptive review and key recommendations. Diabetes Metab Syndr 2021; 15(3): 937-48.
[http://dx.doi.org/10.1016/j.dsx.2021.04.018] [PMID: 33933807]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy